Beebe JS - Search Results

1

Anti-IL21 receptor monoclonal antibody (ATR-107): Safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study.

Hua F, Comer GM, Stockert L, Jin B, Nowak J, Pleasic-Williams S, Wunderlich D, Cheng J, Beebe JS. Hua F, et al. Among authors: beebe js. J Clin Pharmacol. 2014 Jan;54(1):14-22. doi: 10.1002/jcph.158. Epub 2013 Sep 17. J Clin Pharmacol. 2014. PMID: 23913720 Clinical Trial.

2

Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II).

Danese S, Vermeire S, Hellstern P, Panaccione R, Rogler G, Fraser G, Kohn A, Desreumaux P, Leong RW, Comer GM, Cataldi F, Banerjee A, Maguire MK, Li C, Rath N, Beebe J, Schreiber S. Danese S, et al. Gut. 2019 Jan;68(1):40-48. doi: 10.1136/gutjnl-2017-314562. Epub 2017 Dec 15. Gut. 2019. PMID: 29247068 Free PMC article. Clinical Trial.

3

Pharmacokinetics and C-reactive protein modelling of anti-interleukin-6 antibody (PF-04236921) in healthy volunteers and patients with autoimmune disease.

Li C, Shoji S, Beebe J. Li C, et al. Br J Clin Pharmacol. 2018 Sep;84(9):2059-2074. doi: 10.1111/bcp.13641. Epub 2018 Jun 25. Br J Clin Pharmacol. 2018. PMID: 29776017 Free PMC article.

4

A Phase 1 Study to Assess Mass Balance and Absolute Bioavailability of Zimlovisertib in Healthy Male Participants Using a ¹⁴ C-Microtracer Approach.

Singh RSP, Dowty ME, Salganik M, Brodfuehrer JI, Walker GS, Sharma R, Beebe JS, Danto SI. Singh RSP, et al. Among authors: beebe js. Clin Pharmacol Drug Dev. 2022 Jul;11(7):815-825. doi: 10.1002/cpdd.1109. Epub 2022 May 4. Clin Pharmacol Drug Dev. 2022. PMID: 35506501 Free PMC article. Clinical Trial.

5

Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.

Wallace DJ, Strand V, Merrill JT, Popa S, Spindler AJ, Eimon A, Petri M, Smolen JS, Wajdula J, Christensen J, Li C, Diehl A, Vincent MS, Beebe J, Healey P, Sridharan S. Wallace DJ, et al. Among authors: beebe j. Ann Rheum Dis. 2017 Mar;76(3):534-542. doi: 10.1136/annrheumdis-2016-209668. Epub 2016 Sep 26. Ann Rheum Dis. 2017. PMID: 27672124 Free PMC article. Clinical Trial.

6

Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.

Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, Tengowski MW, Wang F, Gualberto A, Beebe JS, Moyer JD. Cohen BD, et al. Among authors: beebe js. Clin Cancer Res. 2005 Mar 1;11(5):2063-73. doi: 10.1158/1078-0432.CCR-04-1070. Clin Cancer Res. 2005. PMID: 15756033

7

Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.

Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfield C, Zhu L, Papacharalambous J, Vincent MS, Peeva E. Gooderham MJ, et al. Among authors: beebe js. JAMA Dermatol. 2019 Dec 1;155(12):1371-1379. doi: 10.1001/jamadermatol.2019.2855. JAMA Dermatol. 2019. PMID: 31577341 Free PMC article. Clinical Trial.

8

PF-03475952: a potent and neutralizing fully human anti-CD44 antibody for therapeutic applications in inflammatory diseases.

Runnels HA, Weber GL, Min J, Kudlacz EM, Zobel JF, Donovan CB, Thiede MA, Zhang J, Alpert RB, Salafia MA, Milici AJ, Burdette D, Bell RR, Beebe JS, Xu X. Runnels HA, et al. Among authors: beebe js. Adv Ther. 2010 Mar;27(3):168-80. doi: 10.1007/s12325-010-0010-0. Epub 2010 Apr 26. Adv Ther. 2010. PMID: 20429046

9

Increased serum enzyme levels associated with kupffer cell reduction with no signs of hepatic or skeletal muscle injury.

Radi ZA, Koza-Taylor PH, Bell RR, Obert LA, Runnels HA, Beebe JS, Lawton MP, Sadis S. Radi ZA, et al. Among authors: beebe js. Am J Pathol. 2011 Jul;179(1):240-7. doi: 10.1016/j.ajpath.2011.03.029. Epub 2011 May 13. Am J Pathol. 2011. PMID: 21703406 Free PMC article.

10

Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate.

Robinson MF, Damjanov N, Stamenkovic B, Radunovic G, Kivitz A, Cox L, Manukyan Z, Banfield C, Saunders M, Chandra D, Vincent MS, Mancuso J, Peeva E, Beebe JS. Robinson MF, et al. Among authors: beebe js. Arthritis Rheumatol. 2020 Oct;72(10):1621-1631. doi: 10.1002/art.41316. Epub 2020 Sep 7. Arthritis Rheumatol. 2020. PMID: 32419304 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

32 results

Search Page

Filters